SEC Comment Letter for BRISTOL MYERS SQUIBB CO (BMY, BMYMP, CELG-RI) (CIK 0000014272) (BMY) — Apr 8, 2022
BRISTOL MYERS SQUIBB CO (BMY, BMYMP, CELG-RI) (CIK 0000014272)
Date: April 8, 2022 · CIK: 0000014272 · Accession: 0000000000-22-003798
AI Filing Summary & Sentiment
File numbers found in text: 001-01136
Letter
United States securities and exchange commission logo April 8, 2022 Giovanni Caforio, M.D. Chairman and Chief Executive Officer Officer Bristol-Myers Squibb Company 430E. 29th Street, 14FL New, York, New York 10016 Re:Bristol-Myers Squibb Company Form 10-K for Fiscal Year Ended December 31, 2020 Filed February 10, 2021 File No. 001-01136 Dear Dr. Caforio: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
April 8, 2022
Giovanni Caforio, M.D.
Chairman and Chief Executive Officer Officer
Bristol-Myers Squibb Company
430E. 29th Street, 14FL
New, York, New York 10016
Re:Bristol-Myers Squibb Company
Form 10-K for Fiscal Year Ended December 31, 2020
Filed February 10, 2021
File No. 001-01136
Dear Dr. Caforio:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences